Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8005403 | 0.96 | ITGB3 (0.49) | CNR2CNR1ITGB3ITGA2BKLK5 | |
| SCHEMBL16315984 | 0.96 | ITGB3 (0.49) | CNR2CNR1ITGB3ITGA2BKLK5 | |
| SCHEMBL16119167 | 0.93 | CNR2 (0.49) | CNR2CNR1ITGB3ITGA2BKLK5 | |
| SCHEMBL13260767 | 0.90 | ITGB3 (0.48) | CNR2CNR1ITGB3ITGA2BKLK5 | |
| SCHEMBL16118744 | 0.90 | ITGB3 (0.48) | CNR2CNR1ITGB3ITGA2BKLK5 | |
| SCHEMBL15711960 | 0.89 | ITGB3 (0.49) | CNR2CNR1ITGB3ITGA2BKLK5 | |
| SCHEMBL7439577 | 0.89 | KLK5 (0.54) | KLK5ITGA4ITGB7 | |
| SCHEMBL8005589 | 0.86 | ITGB3 (0.61) | ITGB3ITGA2BPTPN1ITGA4ITGB7 | |
| SCHEMBL16315983 | 0.86 | ITGB3 (0.61) | ITGB3ITGA2BPTPN1ITGA4ITGB7 | |
| SCHEMBL15593763 | 0.85 | ITGB3 (0.64) | ITGB3ITGA2BKLK5PTPN1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2014152134-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | CNR2 4318/4885CNR1 4079/4885ITGB3 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.